The present disclosure relates to compounds of formulas (A) and (I), pharmaceutically acceptable salts thereof, and solvates of any of the foregoing, pharmaceutical compositions comprising the same, methods of preparing the same, intermediate compounds useful for preparing the same, and methods for treating or prophylaxis of diseases, in particular cancer, such as colorectal cancer, using the same.

##STR00001##

The present invention relates to elastomer compositions comprising adducts between compounds of formula (I) preferably derived from natural sources such as mucic, pyromucic, glucaric, glycaric, galactaric, muconic acid and/or linear derivatives thereof containing ester or amide groups and/or cyclic derivatives thereof with heteroatoms in the ring, such as oxygen or nitrogen, and carbon allotropes in which the carbon is sp.sup.2 hybridized, such as for example carbon nanotubes, graphene or nanographites, carbon black.

Provided herein are lipid compounds that can be used in combination with other lipid components, such as neutral lipids, cholesterol and polymer conjugated lipids, to form lipid nanoparticles for delivery of therapeutic agents (e.g., nucleic acid molecules) for therapeutic or prophylactic purposes, including vaccination. Also provided herein are lipid nanoparticle compositions comprising said lipid compounds.

Provided herein are lipid compounds that can be used in combination with other lipid components, such as neutral lipids, cholesterol and polymer conjugated lipids, to form lipid nanoparticles for delivery of therapeutic agents (e.g., nucleic acid molecules) for therapeutic or prophylactic purposes, including vaccination. Also provided herein are lipid nanoparticle compositions comprising said lipid compounds.

Production of a high efficiency arthropod repellent by chemically transforming a substance used by mosquitoes as an attractant, the lactic acid, as well as lactates, in this case (S)-ethyl lactate, which is an essential attractant for A. aegypti females. The hydroxyl functional group of lactic acid must be transformed into esters, and the carboxylic acid functional group into amides, since esters and amides are functional groups already present in other repellents, such as in the structure of DEET, IR 3535 and dimethyl phthalate. The ester functional group of (S)-ethyl lactate must undergo a reaction in which the acyl functional group is substituted by an amine of interest and the hydroxyl functional group must be acylated. The structure of an attractant, or a derivative thereof, is transformed into a high efficiency repellent.

Production of a high efficiency arthropod repellent by chemically transforming a substance used by mosquitoes as an attractant, the lactic acid, as well as lactates, in this case (S)-ethyl lactate, which is an essential attractant for A. aegypti females. The hydroxyl functional group of lactic acid must be transformed into esters, and the carboxylic acid functional group into amides, since esters and amides are functional groups already present in other repellents, such as in the structure of DEET, IR 3535 and dimethyl phthalate. The ester functional group of (S)-ethyl lactate must undergo a reaction in which the acyl functional group is substituted by an amine of interest and the hydroxyl functional group must be acylated. The structure of an attractant, or a derivative thereof, is transformed into a high efficiency repellent.

A method for producing a diglycolamide molecule having the formula:

##STR00001##

wherein R.sup.1 and R.sup.2 are independently selected from alkyl groups (R) and acyl groups (C(O)R) in which the alkyl groups (R) contain 1-30 carbon atoms and optionally contain an ether or thioether linkage between carbon atoms, and R.sup.5 and R.sup.6 are independently selected from hydrogen atom and alkyl groups containing 1-3 carbon atoms; and one or both pairs of R.sup.1 and R.sup.2 are optionally interconnected to form a ring; the method comprising: combining a diglycolic acid molecule (A) and a secondary amine (B) to form a salt intermediate (C), and heating the salt intermediate (C) to a temperature of 100° C. to 300° C. to form the diglycolamide of Formula (1) in a dehydration process, wherein the method is shown schematically as follows:

##STR00002##

A method for producing a diglycolamide molecule having the formula:

##STR00001##

wherein R.sup.1 and R.sup.2 are independently selected from alkyl groups (R) and acyl groups (C(O)R) in which the alkyl groups (R) contain 1-30 carbon atoms and optionally contain an ether or thioether linkage between carbon atoms, and R.sup.5 and R.sup.6 are independently selected from hydrogen atom and alkyl groups containing 1-3 carbon atoms; and one or both pairs of R.sup.1 and R.sup.2 are optionally interconnected to form a ring; the method comprising: combining a diglycolic acid molecule (A) and a secondary amine (B) to form a salt intermediate (C), and heating the salt intermediate (C) to a temperature of 100° C. to 300° C. to form the diglycolamide of Formula (1) in a dehydration process, wherein the method is shown schematically as follows:

##STR00002##

The present invention relates to a cationic lipid having one or more biodegradable groups located in a lipidic moiety (e.g., a hydrophobic chain) of the cationic lipid. These cationic lipids may be incorporated into a lipid particle for delivering an active agent, such as a nucleic acid. The invention also relates to lipid particles comprising a neutral lipid, a lipid capable of reducing aggregation, a cationic lipid of the present invention, and optionally, a sterol. The lipid particle may further include a therapeutic agent such as a nucleic acid.

The present invention relates to a cationic lipid having one or more biodegradable groups located in a lipidic moiety (e.g., a hydrophobic chain) of the cationic lipid. These cationic lipids may be incorporated into a lipid particle for delivering an active agent, such as a nucleic acid. The invention also relates to lipid particles comprising a neutral lipid, a lipid capable of reducing aggregation, a cationic lipid of the present invention, and optionally, a sterol. The lipid particle may further include a therapeutic agent such as a nucleic acid.